Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26046
Title: Desvenlafaxine in the treatment of major depression: an updated overview.
Austin Authors: Norman, Trevor R ;Olver, James S 
Affiliation: Psychiatry (University of Melbourne)
Issue Date: Jun-2021
Date: 2021-03-11
Publication information: Expert Opinion on Pharmacotherapy 2021; 22(9): 1087-1097
Abstract: Introduction: Major depressive disorder (MDD) remains one of the most prevalent mental health conditions. It is a chronic, relapsing condition and despite multiple treatment options, many patients fail to achieve remission of symptoms. Inadequacy of treatment has stimulated the search for agents with significant therapeutic advantages.Areas covered: This review examines literature concerning the use of desvenlafaxine in the treatment of MDD published since a previous analysis in this journal in 2014. Published papers were identified via a PubMed and Web of Science search and excluded congress presentations. Results from clinical trials in MDD, systematic reviews and post hoc analyses in patient subgroups, are reviewed.Expert opinion: Desvenlafaxine was an effective antidepressant with favourable safety and tolerability in adults. Efficacy was demonstrated in the subgroup of peri- and post-menopausal women with MDD but not in children and adolescents. There is a relatively low potential for drug-drug interactions due to its metabolic profile. Hepatic impairment does not significantly alter dose requirements, whereas severe renal disease requires some adjustments of dose. Desvenlafaxine maybe suitable in patients with comorbid physical illnesses. Desvenlafaxine can be a first line consideration for the treatment of cases of MDD uncomplicated by medical comorbidities.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26046
DOI: 10.1080/14656566.2021.1900826
Journal: Expert Opinion on Pharmacotherapy
PubMed URL: 33706624
Type: Journal Article
Subjects: adolescents
adverse drug events
children
desvenlafaxine
drug-drug interaction
major depressive disorder
mechanism
pharmacokinetics
treatment efficacy
Appears in Collections:Journal articles

Show full item record

Page view(s)

50
checked on Apr 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.